Biotech Values

[jbog]

Does the ASH poster have new topline data, or is it just more detail on what investors already knew

The ASH poster has a couple of updates:

The last we knew they were going to increase the dosing from 8g to 12g. Now they are dosing at 18mg and the response of the 12 mg patients isn't available.

From a safety aspect it looks very clean and they can keep on increasing the dosage which is helping the RO and Plasma Data. They are filling their cohorts very fast so someone has interest.

If you're looking for the Cherry on Top, being the RR, it leaves a little to be desired. Looks like the DOR is not that robust. On the other hand, no other CD47 drug had any RR whatsoever and they are producing breathless Combo results. These were never meant to be mono drugs.

Cart-T and Crisper is stealing the show. They are making enormous strides.